Comparison of Fc N-Glycosylation of Pharmaceutical Products of Intravenous Immunoglobulin G

Willem Jan Fokkink; D Falck; TCM Santbergen; R Huizinga; M Wuhrer; B.C. Jacobs

doi:10.1371/journal.pone.0139828

Comparison of Fc N-Glycosylation of Pharmaceutical Products of Intravenous Immunoglobulin G

Willem Jan Fokkink, D Falck, TCM Santbergen, R Huizinga, M Wuhrer, B.C. Jacobs

Research output: Contribution to journal › Article › Academic › peer-review

12 Citations (Scopus)

3 Downloads (Pure)

Abstract

Intravenous immunoglobulin (IVIg) products from different pharmaceutical companies vary in composition, in part because of the selected blood donors and production process. N-glycosylation of the Fc-portion of IgG varies between blood donors and may influence both the side-effects and therapeutic effectiveness of IVIg. At present, the variation in Fc N-glycosylation between IVIg products has not been defined. Utilizing mass spectrometry, we performed relative quantitation of the Fc N-glycosylation of IgG, assessing a total of 154 unique lot numbers of IVIg. Seven products showed comparable Fc N-glycosylation, with only one product differing from the others in all glycosylation features ( galactosylation, sialylation, fucosylation and bisecting N-acetylglucosamine). However, the mean difference did not exceed 3%. Within product variation was present to a minor degree, but largely indistinguishable from analytical variation. In conclusion, we expect that the minor variation in Fc N-glycosylation between IVIg products has a small effect, if any, on the biological activity.

Original language	Undefined/Unknown
Journal	PLoS One (print)
Volume	10
Issue number	10
DOIs	https://doi.org/10.1371/journal.pone.0139828
Publication status	Published - 2015

Access to Document

10.1371/journal.pone.0139828

REPUB_89207_OA.pdfFinal published version, 631 KB

http://hdl.handle.net/1765/89207

Cite this

@article{a9708791ce0d464b8bd2f0a066604c0d,

title = "Comparison of Fc N-Glycosylation of Pharmaceutical Products of Intravenous Immunoglobulin G",

abstract = "Intravenous immunoglobulin (IVIg) products from different pharmaceutical companies vary in composition, in part because of the selected blood donors and production process. N-glycosylation of the Fc-portion of IgG varies between blood donors and may influence both the side-effects and therapeutic effectiveness of IVIg. At present, the variation in Fc N-glycosylation between IVIg products has not been defined. Utilizing mass spectrometry, we performed relative quantitation of the Fc N-glycosylation of IgG, assessing a total of 154 unique lot numbers of IVIg. Seven products showed comparable Fc N-glycosylation, with only one product differing from the others in all glycosylation features ( galactosylation, sialylation, fucosylation and bisecting N-acetylglucosamine). However, the mean difference did not exceed 3%. Within product variation was present to a minor degree, but largely indistinguishable from analytical variation. In conclusion, we expect that the minor variation in Fc N-glycosylation between IVIg products has a small effect, if any, on the biological activity.",

author = "Fokkink, {Willem Jan} and D Falck and TCM Santbergen and R Huizinga and M Wuhrer and B.C. Jacobs",

year = "2015",

doi = "10.1371/journal.pone.0139828",

language = "Undefined/Unknown",

volume = "10",

journal = "PLoS ONE",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "10",

}

TY - JOUR

T1 - Comparison of Fc N-Glycosylation of Pharmaceutical Products of Intravenous Immunoglobulin G

AU - Fokkink, Willem Jan

AU - Falck, D

AU - Santbergen, TCM

AU - Huizinga, R

AU - Wuhrer, M

AU - Jacobs, B.C.

PY - 2015

Y1 - 2015

N2 - Intravenous immunoglobulin (IVIg) products from different pharmaceutical companies vary in composition, in part because of the selected blood donors and production process. N-glycosylation of the Fc-portion of IgG varies between blood donors and may influence both the side-effects and therapeutic effectiveness of IVIg. At present, the variation in Fc N-glycosylation between IVIg products has not been defined. Utilizing mass spectrometry, we performed relative quantitation of the Fc N-glycosylation of IgG, assessing a total of 154 unique lot numbers of IVIg. Seven products showed comparable Fc N-glycosylation, with only one product differing from the others in all glycosylation features ( galactosylation, sialylation, fucosylation and bisecting N-acetylglucosamine). However, the mean difference did not exceed 3%. Within product variation was present to a minor degree, but largely indistinguishable from analytical variation. In conclusion, we expect that the minor variation in Fc N-glycosylation between IVIg products has a small effect, if any, on the biological activity.

AB - Intravenous immunoglobulin (IVIg) products from different pharmaceutical companies vary in composition, in part because of the selected blood donors and production process. N-glycosylation of the Fc-portion of IgG varies between blood donors and may influence both the side-effects and therapeutic effectiveness of IVIg. At present, the variation in Fc N-glycosylation between IVIg products has not been defined. Utilizing mass spectrometry, we performed relative quantitation of the Fc N-glycosylation of IgG, assessing a total of 154 unique lot numbers of IVIg. Seven products showed comparable Fc N-glycosylation, with only one product differing from the others in all glycosylation features ( galactosylation, sialylation, fucosylation and bisecting N-acetylglucosamine). However, the mean difference did not exceed 3%. Within product variation was present to a minor degree, but largely indistinguishable from analytical variation. In conclusion, we expect that the minor variation in Fc N-glycosylation between IVIg products has a small effect, if any, on the biological activity.

U2 - 10.1371/journal.pone.0139828

DO - 10.1371/journal.pone.0139828

M3 - Article

VL - 10

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 10

ER -